Follicular Lymphoma

Follicular lymphoma is one of the most common kinds of non-Hodgkin lymphoma. Its progression rate varies widely, though it tends to spread slowly and has few symptoms. Patients with follicular lymphoma usually survive ten years or longer.
What is Follicular Lymphoma?

Follicular lymphoma is a cancer of the B-cells that accounts for around one third of all cases of lymphoma. The cancer is a form of non-Hodgkin lymphoma that usually affects adults, with an average age-at-diagnosis of 60. Follicular lymphoma is more common among women than among men.

Read More

Overview

Feature Articles

Latest Follicular Lymphoma News and Research

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

New integrative NGS panel for analysis of standard and novel biomarkers in lymphoid neoplasms

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

SwRI researchers part of two collaborative teams receive SAMF bioscience grants

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

Prolonged shedding and multiple mutations 154 days after initial SARS-CoV-2 diagnosis reported

MDC researchers develop a potent weapon against lymphomas

MDC researchers develop a potent weapon against lymphomas

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

Study: CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Yale and AI Therapeutics launch clinical trial of potential COVID-19 drug

Combining two immunotherapies into a single treatment found to be more effective

Combining two immunotherapies into a single treatment found to be more effective

Study shows potential new approach to treating two common subtypes of lymphoma

Study shows potential new approach to treating two common subtypes of lymphoma

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

Next-generation sequencing can detect genetic alterations specific to follicular lymphoma

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

Cancer patients share survivorship story, celebrate strength and self-care

Cancer patients share survivorship story, celebrate strength and self-care

HCA Healthcare UK introduces ground-breaking new blood cancer treatment

HCA Healthcare UK introduces ground-breaking new blood cancer treatment

T-cells play key role in how the body fights follicular lymphoma

T-cells play key role in how the body fights follicular lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

Phase 2 results on tazemetostat EZH2 inhibitor to be presented at ESMO 2018

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma